Forbes

This year will be regarded as an inflection point for the treatment of glioblastoma, a rare and aggressive form of brain cancer that carries a median survival time of around 15 to 18 months, said Carl June, professor at the University of Pennsylvania Perelman School of Medicine and renowned immunologist.